文献速递神经MR

比较临床可用的动态磁敏感对比后处理软件在治疗后高级别胶质瘤中鉴别进展与假性进展的作用

Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
PubMed 文献 · Eur J Radiol · 2023-09-01

这项回顾性研究比较了西门子Syngo.via与Olea Sphere两款DSC灌注MRI软件计算归一化相对脑血容量(rCBV)在治疗后高级别胶质瘤中鉴别肿瘤进展与假性进展的表现。41例患者共49个新发或增大的强化病灶(进展40个、假性进展9个),两款软件的最佳rCBV阈值分别为1.31和2.40,AUC分别为0.74和0.78,阈值差异有统计学意义,评分者间信度为0.85。作者认为不同软件得出的rCBV阈值显著不同,医生可能需在机构层面确定所用灌注软件的独特数值以提高诊断准确性。

要点

  • 西门子Syngo.via与Olea Sphere所得rCBV最佳阈值分别为1.31与2.40,两者差异有统计学意义。
  • 两软件鉴别进展与假性进展的AUC分别为0.74(Syngo.via)与0.78(Olea)。
  • 两名评分者间信度为0.85。

核心结论

  • 不同临床可用的MRI DSC灌注软件包在鉴别治疗后高级别胶质瘤肿瘤进展与假性进展时得出的rCBV阈值显著不同。

研究设计与样本

  • 回顾性研究,纳入41例患者(18例女性;中位年龄59岁,范围21-77岁)共49个治疗后新发或增大的强化病灶(肿瘤进展40个、假性进展9个)。

关键影像表现/征象

  • 基于T1-CE勾画的感兴趣区转移至rCBV图,rCBV以均值计算并以对侧表现正常白质归一化。
  • Syngo.via与Olea Sphere处理的rCBV图均与T1-CE进行共配准。

诊断标准与关键数值

  • Syngo.via最佳rCBV阈值为1.31,AUC为0.74。
  • Olea最佳rCBV阈值为2.40,AUC为0.78。
  • 两软件最佳rCBV阈值显著不同,阈值由Youden指数确定。
  • 两名评分者间信度为0.85,采用组内相关系数评估。

临床应用与阅片要点

  • 作者认为医生可能需在机构层面确定所用灌注软件包的独特数值,以在面对该临床挑战时最大化诊断准确性。
  • 作者指出,结合现行DSC灌注推荐,将改善多中心可比性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: The purpose of this retrospective study was to compare two, widely available software packages for calculation of Dynamic Susceptibility Contrast (DSC) perfusion MRI normalized relative Cerebral Blood Volume (rCBV) values to differentiate tumor progression from pseudoprogression in treated high-grade glioma patients.

MATERIAL AND METHODS: rCBV maps processed by Siemens Syngo.via (Siemens Healthineers) and Olea Sphere (Olea Medical) software packages were co-registered to contrast-enhanced T1 (T1-CE). Regions of interest based on T1-CE were transferred to the rCBV maps. rCBV was calculated using mean values and normalized using contralateral normal- appearing white matter. The Wilcoxon test was performed to assess for significant differences, and software-specific optimal rCBV cutoff values were determined using the Youden index. Interrater reliability was evaluated for two raters using the intraclass correlation coefficient.

RESULTS: 41 patients (18 females; median age = 59 years; range 21-77 years) with 49 new or size-increasing post-treatment contrast-enhancing lesions were included (tumor progression = 40 lesions; pseudoprogression = 9 lesions). Optimal rCBV cutoffs of 1.31 (Syngo.via) and 2.40 (Olea) were significantly different, with an AUC of 0.74 and 0.78, respectively. Interrater reliability was 0.85.

DISCUSSION: We demonstrate that different clinically available MRI DSC-perfusion software packages generate significantly different rCBV cutoff values for the differentiation of tumor progression from pseudoprogression in standard-of-care treated high grade gliomas. Physicians may want to determine the unique value of their perfusion software packages on an institutional level in order to maximize diagnostic accuracy when faced with this clinical challenge. Furthermore, combined with implementation of current DSC-perfusion recommendations, multi-center comparability will be improved.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Nierobisch N, Ludovichetti R, Kadali K, et al. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma. Eur J Radiol. 2023. PMID: 37666072. doi:10.1016/j.ejrad.2023.111076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。